Cell Cycle Analysis Market Research Report By Product & Service (Reagents & Consumables, Instruments, Accessories, Software, Service), By Technique (Flow Cytometry, PCR, Cell Microarrays, Microscopy, Spectrophotometry, High Content Screening, Other Techniques), By Process (Cell Identification, Cell Viability, Cell Signaling Pathways/Signal Transduction, Cell Proliferation, Cell Counting and Quality Control, Cell Interaction, Cell Structure Study, Target Identification and Validation, Single-Cell Analysis), By End User (Pharmaceutical & Biot

Cell Cycle Analysis Market Overview

Cell Cycle Analysis Market Size was valued at USD 20.20 Billion in 2023. The Global Cell Cycle Analysis industry is projected to grow from USD 22.41 Billion in 2024 to USD 51.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.98% during the forecast period (2024 - 2032).Increased medication discovery efforts, fast urbanization and digitalization, and improved healthcare infrastructure are becoming more common and are the key market drivers boosting the expansion of the market.

Cell Cycle Analysis Market Trends

• Increasing number of drug discovery initiatives is driving the market growth

Market CAGR for Cell Culture Services is being driven by the rising number of drug discovery initiatives. The phrase "cell analysis" refers to a broad category of technologies that are employed to examine the genetic and phenotypic properties of a cell. Understanding cellular constituents, including DNA, RNA, protein composition, and cellular metabolites, is essential to gaining insights into the mechanisms behind cellular functionality. Cell analysis is frequently used to comprehend population heterogeneity, locate interesting minority subpopulations, and uncover distinctive properties of individual cells.

Additionally, in order to comprehend related difficulties, the use of cell-based screening assays in drug discovery activities has risen. Furthermore, the use of cell-based assays in the drug discovery process has become more significant as a result of the vast amounts of data created by developments in cell biology, bioinformatics, molecular biology, genomics, and proteomics. Analogously, several targets for drug screening studies have been produced by the Human Genome Project. The creation of cell-based assays for primary and secondary screening in drug discovery has increased due to the recent sharp increase in therapeutic targets and drug leads. With the advancement of high-throughput screening (HTS) and high-content screening (HCS) technologies, the dependability of cell analysis has increased.

Cell analysis technology is advancing due to the increased incidence of chronic illnesses and the creation of more effective cancer treatments. To help researchers better understand the processes of cancer progression and immune response, Fluidigm Corporation, a US-based company, has announced the debut of its REAP-seq (RNA expression and protein sequencing) technology. High-throughput equipment has been introduced as a result of the funding and growing need for analytical tools for creative research. This equipment now has qualities like automation, high sensitivity, and accuracy thanks to several developments, all of which help with the analysis of rare samples.

For instance, an American Cancer Society 2022 report anticipated that 1,918,030 new cases of cancer will be diagnosed in the US in 2022. Moreover, researchers frequently employ cell analysis in cancer to determine different criteria. Researchers profiled the tumor microenvironment (TME) at single-cell resolution using 226 samples from 10 different solid cancer types in a pan-cancer analysis that was published in the November 2022 issue of the journal Nature. This study highlighted the similarities and variability of heterogeneous CAFs (cancer-associated fibroblasts). This results in driving the cell culture service market revenue.

Cell Cycle Analysis Market Segment Insights

Cell Cycle Analysis Product & Service Insights

The Cell Cycle Analysis Market segmentation, based on Product & Service, includes Reagents & Consumables, Instruments, Accessories, Software, and Service. In 2023, the Reagents & Consumables segment dominated the market. This is because the significant portion can be attributed to the high degree of usability of separation products, the widespread use of cell sorting beads, the regular acquisition of buffers and reagents, and the rising demand for test kits. The segment is growing as a result of the rising prevalence of target diseases and the ongoing requirement for consumables needed for assays during scientific operations.

Cell Cycle Analysis Technique Insights

The cell biology service Market segmentation, based on Technique, includes Flow Cytometry, PCR, Cell Microarrays, Microscopy, Spectrophotometry, High Content Screening, and Other Techniques. In 2023, the Flow Cytometry generated the most income. A flexible and effective method for both quantitative and qualitative cell examination is flowing cytometry. It can provide useful information for research and therapeutic applications by analyzing cells according to their size, granularity, and fluorescence characteristics.

Cell Cycel Analysis Process Insights

The Cell Biology Services Market segmentation, based on Process, includes Target identification and validation, cell interaction, cell structure study, cell viability, cell signaling pathways/signal transduction, cell proliferation, cell counting, and quality control, Single Cell Analysis, and Cell Identification. In 2023, the Single-Cell Analysis segment dominated the market. Biopharma is increasingly using single-cell techniques to aid in the identification of new drugs. The development of single cell analysis that is compatible with FFPE has made it possible for biopharma to access older samples, increasing the usefulness of these techniques. Falling sequencing costs and new options catering to both high- and low-throughput users are opening up single-cell analysis.

Cell Cycle Analysis End User Insights

The Cell Analysis Market segmentation, based on End User, comprises Pharmaceutical & Biotechnology Companies, Academic and Research Institutes, Hospitals and Clinical Testing Laboratories, and Other End Users. In 2023, the Pharmaceutical & Biotechnology Companies category generated the most income. This is because a variety of procedures, including cell identification, viability, proliferation, structural analysis, signaling pathways, counting, quality control, target identification, validation, cell interaction, and single-cell analysis, are carried out using cell analysis products. These businesses mostly rely on cell analysis techniques for drug development, chemical screening, and testing.

Figure1: Cell Analysis Market, by End User, 2023 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Cell Cycle Analysis Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Cell Biology Services market area will dominate this market, owing to the growing demand for analytical tools for creative research, and the funding that follows will boost market growth in this region.

Further, the major countries investigated in the market report are China, Japan, India, Australia, South Korea, Germany, France, the UK, Italy, and Spain.

Figure2: Cell Analysis Market Share By Region 2023 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe Cell Analysis market has the second-largest portion of the market. This is due to the increasing emphasis on stem cell research and regenerative medicine. Further, the German Cell Biology Services market maintained the largest market share, and the UK  Cell Cycle Analysis market was the European market with the quickest rate of growth.

The Asia-Pacific Cell Cycle Analysis Market is anticipated to expand between 2024 and 2032 at the quickest CAGR. This is due to the rising prevalence of chronic diseases in the quickly aging population. Moreover, China’s market maintained the largest market share, and the Indian Cell Services market was the Asia-Pacific region's fastest-growing market.

 Cell Cycle Analysis Key Market Players& Competitive Insights

Leading market players are putting a lot of money into R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure an increasingly cutthroat and dynamic market, the Cell Cycle Analysis industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the global Cell Cycle Analysis Market industry to help customers and expand the market segment. In recent years, the Cell Biology Diagnosis| Cell Cycle Analysis industry has provided some of the biggest benefits to medicine. Major players in the Cell Culture Services| Cell Analysis market, including Procter & Gamble (USA), Agilent Technologies (USA), General Electric (USA), Becton, Dickinson and Company (USA), Danaher (USA), Thermo Fisher Scientific (US), and Olympus Corporation (Japan), are engaging in research and development activities in an effort to boost market demand.

American company Bio-Rad Laboratories, Inc. develops and produces specialized technology products for the clinical diagnostics and life science research industries. The company was started in Berkeley by married University of California, Berkeley students David and Alice Schwartz, California, in 1952. Bio-Rad is a global company with operations centered in Hercules, California. In March 2023, Bio-Rad was given the iQ-Check kits that the company sells, which were approved by AOAC International and AFNOR for use with the CFX Opus Deep well Real-time PCR System.

Serving more than 155 countries, Illumina, Inc. is an American biotechnology firm with its headquarters located in San Diego, California. In Illumina was established on April 1, 1998, and it designs, produces, and sells integrated solutions for the study of biological function and genetic diversity. Proteomics, genotyping and gene expression, and sequencing are among the markets that the company supports with its range of goods and services. In September 2022, Illumina introduced NovaSeq X and NovaSeq X Plus. Compared to Illumina's earlier machines, which could only sequence 7,500 genomes annually, the NovaSeq X Plus can sequence 20,000 genomes annually and produce up to 16 Tb of data every run. Redeveloped reagents, dyes, and polymerases are included in the series and can be delivered at room temperature.

Key Companies in the Cell Cycle Analysis market include

• Danaher (US)


• Thermo Fisher Scientific (US)


• Becton, Dickinson and Company (US)


• General Electric (US)


• Merck KGaA (US)


• Agilent Technologies (US)


• Olympus Corporation (Japan)


• Miltenyi Biotec (US)


• Bio-Rad Laboratories (US)


• BioStatus Limited (UK)


• Fluidigm Corporation (US)


• NanoCellect Biomedical (US)


• Cell Biolabs (US)


• Illumina (US)

Cell Biology Services Industry Developments

October 2022: Innovation life science reagent and device firms Takara Bio USA, Inc., and BioExcel Diagnostic tools are developing and verifying a high-level, comprehensive technique for diagnosing infectious diseases based on syndromic markers. A fully owned subsidiary of Takara Bio Inc. is Takara Bio USA, Inc.

September 2022: QIAGEN and Neuron23 Inc., the first biotechnology company devoted to creating precision drugs based on genetic neurological and immunological disorders, declared the signing of an agreement to develop a partner screening for Neuron23's brain penetrant blocker for Parkinson's disease.

Cell Biology Services Market Segmentation

Cell Biology Services Product & Service Outlook

• Reagents & Consumables


• Instruments


• Accessories


• Software


• Service

Cell Biology Services Technique Outlook

• Flow Cytometry


• PCR


• Cell Microarrays


• Microscopy


• Spectrophotometry


• High Content Screening


• Other Techniques

Cell Biology Services Process Outlook

• Cell Identification


• Cell Viability


• Cell Signaling Pathways/Signal Transduction


• Cell Proliferation


• Cell Counting and Quality Control


• Cell Interaction


• Cell Structure Study


• Target Identification and Validation


• Single-Cell Analysis

Cell Biology Services End User Outlook

• Pharmaceutical & Biotechnology Companies


• Hospitals and Clinical Testing Laboratories


• Academic and Research Institutes


• Other End Users

Cell Biology Services Regional Outlook

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Attribute/Metric	Details
Market Size 2023	USD 20.20 Billion
Market Size 2024	USD 22.41 Billion
Market Size 2032	USD 51.34 Billion
Compound Annual Growth Rate (CAGR)	10.98% (2024-2032)
Base Year	2023
Market Forecast Period	2024-2032
Historical Data	2019- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product & Service, Technique, Process, End User and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	China, Japan, India, Australia, South Korea, Brazil, Germany, France, UK, Italy, and Spain
Key Companies Profiled	Procter & Gamble (USA), Agilent Technologies (USA), General Electric (USA), Becton, Dickinson and Company (USA), Danaher (USA), Thermo Fisher Scientific (US), and Olympus Corporation (Japan).
Key Market Opportunities	Increasing number of drug discovery initiatives
Key Market Dynamics	Increased activity in medication research, fast urbanization, and digitalization